Skip to main content
TipRanks
Go Ultimate75% OFF

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) AI Stock Analysis

0 Followers
HK:1858

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H

(HKEX:1858)

Select Model
Rating:72Outperform
Price Target:HKD 7.50â–²(7.91% Upside)
Action:reiterated
Date:11/05/26

The score is supported primarily by strong profitability, minimal debt, and positive free cash flow. Attractive income and reasonable valuation add support, but declining revenue, volatile cash generation, and mixed-to-weak technical trends limit the overall score.

Positive Factors
High ProfitabilitySustained high gross and net margins indicate that the orthopedic implant business retains meaningful earnings power after production and operating costs. This profitability provides internal funding for research, commercial investment, and resilience while supporting durable returns through the next several quarters.
Negative Factors
Uneven Revenue GrowthThe revenue trajectory has been inconsistent, with a sharp 2024 decline, a 2025 rebound, and softer TTM performance. This uneven pattern reduces visibility into demand and makes it harder to assess whether recent profitability can be sustained as the business moves through the next several quarters.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) vs. iShares MSCI Hong Kong ETF (EWH)

-60%-50%-40%-30%-20%-10%0%10%20%HK:1858-57.52%EWH+4.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 4.14B
Dividend Yield
5.79%
Average Volume (3M)
587.92K
Price to Earnings (P/E)
16.4
Beta (1Y)
1.00
Revenue Growth
-9.00%
EPS Growth
10.62%
Country
Hong Kong
Employees
1,078
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Beijing Chunlizhengda Medical Instruments Co., Ltd. operates as a specialist in orthopedic medical devices. Its core activities encompass the development, manufacturing, and marketing of surgical implants, instruments, and related medical supplies. W...

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary

Strong overall financial profile, led by an exceptionally strong balance sheet and high profitability. Positive free cash flow supports the score, while declining revenue, weaker operating cash flow, and historical volatility remain concerns.

Income Statement

78Positive

Balance Sheet

94Very Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue909.88M1.05B805.86M1.21B1.20B1.11B
Gross Profit575.16M653.40M516.49M875.89M913.53M844.03M
EBITDA301.97M311.67M169.32M340.65M366.96M362.75M
Net Income269.00M272.54M124.99M277.82M307.72M322.36M
Balance Sheet
Total Assets3.65B3.66B3.47B3.65B3.41B3.00B
Cash, Cash Equivalents and Short-Term Investments2.17B2.22B1.89B2.10B1.72B1.74B
Total Debt2.39M3.28M866.44K1.75M1.31M1.23M
Total Liabilities530.11M674.14M644.39M770.33M690.07M530.58M
Stockholders Equity3.12B2.99B2.82B2.88B2.72B2.47B
Cash Flow
Free Cash Flow312.17M351.97M-51.07M478.47M16.10M-34.62M
Operating Cash Flow354.46M409.57M-1.90M511.71M41.01M164.79M
Investing Cash Flow99.57M-124.01M55.84M-81.56M-762.61M-190.35M
Financing Cash Flow-145.29M-28.75M-183.14M-121.33M-59.04M1.07B

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis

Technical Analysis SentimentNegative
Last Price6.95

Price Trends

50DMA7.48Negative
100DMA8.17Negative
200DMA9.84Negative

Market Momentum

MACD-0.11Positive
RSI35.21Neutral
STOCH12.40Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1858, the sentiment is Negative. The current price of 6.95 is below the 20-day moving average (MA) of 7.38, below the 50-day MA of 7.48, and below the 200-day MA of 9.84, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 35.21 is Neutral, neither overbought nor oversold. The STOCH value of 12.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1858.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:1858 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1789HK:178977OutperformHKD 5.10B10.8813.24%2.72%16.15%31.89%
HK:2190HK:219074OutperformHKD 6.08B15.309.76%2.11%39.30%109.37%
HK:1858HK:185872OutperformHKD 4.81B16.408.83%5.79%-9.00%10.62%
HK:2235HK:223560NeutralHKD 2.76B26.924.08%―94.80%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:9996HK:999644NeutralHKD 2.34B-14.06-7.65%―21.23%36.89%
HK:0853HK:085341NeutralHKD 11.65B31.256.07%―-3.62%―

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%HK:1858HK:0853HK:9996HK:2190HK:1789HK:2235Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:1858 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:1858Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H6.95-9.53-57.82%
HK:0853MicroPort Scientific Corp6.08-4.61-43.17%
HK:9996Peijia Medical Ltd.3.49-1.83-34.40%
HK:2190Zylox-Tonbridge Medical Technology Co., Ltd. Class H17.07-7.41-30.28%
HK:1789AK Medical Holdings Ltd.4.34-1.11-20.33%
HK:2235MicroTech Medical (Hangzhou) Co., Ltd. Class H6.49-0.31-4.56%

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events

Chunlizhengda appoints Wendy Kam and changes Hong Kong business location

Nov 20, 2026

Beijing Chunlizhengda Medical Instruments Co., Ltd. appointed Kam Mei Ha Wendy as company secretary, authorized representative and Hong Kong process agent, effective 20 November 2026, following the cessation of Mr. Ip Pui Sum from those roles. The co...

Chunli Medical Releases Unaudited Third-Quarter 2026 Results for Dual-Listed Investors

Oct 30, 2026

Beijing Chunlizhengda Medical Instruments Co., Ltd., a PRC-based medical devices manufacturer listed in Hong Kong and Shanghai, reports unaudited financial results under Chinese Accounting Standards for Business Enterprises. The group operates within...

Chunlizhengda Board to Review Q3 Results and Interim Dividend

Oct 15, 2026

Beijing Chunlizhengda Medical Instruments Co., Ltd. has scheduled a board meeting for 30 October 2026 to approve the group’s third-quarter results for the nine months ended 30 September 2026 and to authorize their publication. The board will also con...

Chunlizhengda Faces Temporary Governance Gap After Death of Key Hong Kong Officer

Sep 11, 2026

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the passing of Mr. Ip Pui Sum, who served for a decade as company secretary, authorised representative in Hong Kong and process agent for legal notices. The board praised his dedication an...

Beijing Chunlizhengda Reports Stable Interim Balance Sheet for First Half of 2026

Aug 28, 2026

Beijing Chunlizhengda Medical Instruments has reported its unaudited consolidated interim results for the six months ended 30 June 2026, prepared in accordance with PRC accounting standards and Hong Kong disclosure rules. The announcement shows the g...

Beijing Chunlizhengda Declares Interim Cash Dividend for First Half of 2026

Aug 28, 2026

Beijing Chunlizhengda Medical Instruments Co., Ltd. has declared an interim ordinary cash dividend of RMB 1.3 per 10 shares for the six months ended 30 June 2026, underscoring its commitment to returning capital to shareholders. Key dates and payment...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026